DrugPatentWatch Database Preview
Drugs in Development Information for Avigan
» See Plans and Pricing
What is the development status for investigational drug Avigan?
Avigan is an investigational drug.
There have been 16 clinical trials for Avigan.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.
The most common disease conditions in clinical trials are Hemorrhagic Fever, Ebola, Respiratory Distress Syndrome, Adult, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti, and Institut National de la Santé Et de la Recherche Médicale, France.
There are one hundred and twenty-six US patents protecting this investigational drug and one international patent.
Summary for Avigan
| US Patents | 126 |
| International Patents | 1,262 |
| US Patent Applications | 306 |
| WIPO Patent Applications | 246 |
| Japanese Patent Applications | 126 |
| Clinical Trial Progress | Phase 2 (2020-05-01) |
| Vendors | 86 |
Recent Clinical Trials for Avigan
| Title | Sponsor | Phase |
|---|---|---|
| Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy | Koja Regional Public Hospital | Phase 1/Phase 2 |
| Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy | Hayandra Peduli Foundation | Phase 1/Phase 2 |
| Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions | Novagenix Bioanalytical Drug R&D Center | Phase 1 |
Clinical Trial Summary for Avigan
Top disease conditions for Avigan
Top clinical trial sponsors for Avigan
US Patents for Avigan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Avigan | Start Trial | Methods and compositions for inhibition of polymerase | BioCryst Pharmaceuticals, Inc. (Durham, NC) | Start Trial |
| Avigan | Start Trial | Methods of preparing inhibitors of influenza viruses replication | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Avigan | Start Trial | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (Monrovia, CA) | Start Trial |
| Avigan | Start Trial | Substituted nucleosides, nucleotides and analogs thereof | Alios BioPharma, Inc. (South San Francisco, CA) | Start Trial |
| Avigan | Start Trial | Potent anti-influenza A neuraminidase subtype N1 antibody | The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Avigan
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Avigan | Australia | AU2011315902 | 2030-10-15 | Start Trial |
| Avigan | Australia | AU2017200471 | 2030-10-15 | Start Trial |
| Avigan | Brazil | BR112013009029 | 2030-10-15 | Start Trial |
| Avigan | Canada | CA2813783 | 2030-10-15 | Start Trial |
| Avigan | China | CN103429245 | 2030-10-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
